Resonance Health Reports 53% Revenue Growth for 1H FY26
Resonance Health Limited (ASX: RHT) achieved a 53% revenue growth for the half-year ended 31 December 2025, with revenue increasing to AU$8.0 million from AU$5.2 million in 1H FY25. The company reported a normalised EBITDA of AU$1.6 million, with a 20% operating margin, compared to a loss in the previous period. Statutory NPAT for 1H FY26 stood at AU$1.5 million, a significant turnaround from the AU$1.0 million loss in 1H FY25.
The company also achieved positive operating cash flow and continued progress in its major global pharmaceutical clinical trials and TrialsWest clinic network expansion. Additionally, Resonance Health’s SaMD (Software as a Medical Device) pipeline now exceeds AU$10 million, while its Non-Invasive Liver Fibrosis device completed its extended proof-of-concept trial. The company has maintained its FY26 guidance of AU$17 million in revenue and AU$2 million in EBITDA.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Resonance Health Reports 53% Revenue Growth for 1H FY26
Resonance Health Limited (ASX: RHT) achieved a 53% revenue growth for the half-year ended 31 December 2025, with revenue increasing to AU$8.0 million from AU$5.2 million in 1H FY25. The company reported a normalised EBITDA of AU$1.6 million, with a 20% operating margin, compared to a loss in the previous period. Statutory NPAT for 1H FY26 stood at AU$1.5 million, a significant turnaround from the AU$1.0 million loss in 1H FY25.
The company also achieved positive operating cash flow and continued progress in its major global pharmaceutical clinical trials and TrialsWest clinic network expansion. Additionally, Resonance Health’s SaMD (Software as a Medical Device) pipeline now exceeds AU$10 million, while its Non-Invasive Liver Fibrosis device completed its extended proof-of-concept trial. The company has maintained its FY26 guidance of AU$17 million in revenue and AU$2 million in EBITDA.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au